To include your compound in the COVID-19 Resource Center, submit it here.

Adolor meets Phase III POI endpoint

ADLR said that in a Phase III trial (14CL313) in 510 patients with post-operative ileus (POI), both 6 mg and 12

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE